ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Antibacterial activity of bioactive anthraquinones isolated from Cassia tora L. against pathogenic intestinal microorganisms.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Antimicrobial resistance (AMR) poses a major global health challenge, particularly in intestinal infections where the efficacy of conventional antibiotics is rapidly declining. The rising prevalence of antibiotic-resistant pathogens underscores the urgent need for alternative antimicrobial agents with favorable activity profiles. This study evaluated the antibacterial potential of bioactive anthraquinones isolated from Cassia tora L. seeds against clinically relevant intestinal pathogens and probiotic bacteria. Five key anthraquinones, rhein, physcion, anthraquinone-2-carboxylic acid, emodin, and aloe-emodin, were identified and tested for their antibacterial activity. The anthraquinone metabolites exhibited strong antibacterial activity against pathogenic bacteria (Escherichia coli, Staphylococcus aureus, Clostridium difficile, etc.), while showing moderate to relatively lower inhibitory effects against beneficial probiotic strains such as Clostridium butyricum, Bifidobacterium bifidum, and Lactobacillus casei. The MIC profiles indicate relative or modest selectivity toward pathogens, rather than a complete sparing of probiotic species. Molecular docking analysis revealed that these metabolites bind favorably to key bacterial resistance proteins, often surpassing ciprofloxacin in binding affinity, supporting their observed antibacterial activity. Together, these results suggest that C. tora anthraquinones preferentially inhibit intestinal pathogens, maintaining a comparative margin of safety for beneficial gut flora. Anthraquinones isolated from C. tora seeds exhibit potent antibacterial activity toward pathogenic intestinal bacteria and relatively reduced activity against probiotic strains, reflecting selective preference in intestinal bacteria. These findings support their potential as natural antimicrobial candidates for managing intestinal infections and contributing to AMR mitigation. Nonetheless, the measurable inhibitory effects on probiotic species emphasize the need for careful dose optimization and microbiome-conscious therapeutic strategies. Further studies focusing on the mechanism of action, pharmacokinetics, toxicity, and in vivo efficacy are required to evaluate their clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.